Business context and reporting period
Source identification: The supplied filing is Owens & Minor, Inc.’s Form 10-Q for the quarter and six months ended June 30, 2023—not a filing for Accendra Health Inc. The summary below reflects the filing text provided; confirm the issuer before relying on it.
Owens & Minor operates Products & Healthcare Services, which includes distribution, logistics and medical products, and Patient Direct, which supplies home healthcare products and services. Patient Direct includes Apria, acquired in March 2022.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net revenue | $2.563 billion | $2.500 billion | $5.086 billion | $4.907 billion |
| Gross margin | $519.4 million (20.26%) | $532.5 million (21.30%) | $1.017 billion (19.99%) | $906.0 million (18.46%) |
| Operating income | $10.8 million | $75.1 million | $20.6 million | $136.1 million |
| Net income (loss) | $(28.2) million | $28.6 million | $(52.7) million | $67.9 million |
| Diluted EPS | $(0.37) | $0.37 | $(0.70) | $0.89 |
- Segment results: Q2 revenue was $1.931 billion for Products & Healthcare Services (up 0.2%) and $632.5 million for Patient Direct (up 10.5%). Segment operating income was $2.9 million and $59.1 million, respectively, versus $61.2 million and $52.3 million a year earlier. For the first half, Products & Healthcare Services revenue fell 5.3% and operating income fell to $4.8 million; Patient Direct revenue rose 46.6% and operating income rose to $104.9 million.
- Cash flow: First-half operating cash flow was $471.5 million, versus $169.5 million; investing cash outflow was $65.7 million, versus $1.745 billion, which included the Apria acquisition; financing cash outflow was $183.1 million, versus $1.581 billion of inflow. Cash, cash equivalents and restricted cash ended at $309.1 million, up $222.9 million from year-end.
- Balance sheet and liquidity: At June 30, cash and cash equivalents were $286.3 million; current assets were $2.262 billion and current liabilities $1.692 billion. Total debt was $2.334 billion, including $2.310 billion of long-term debt; total equity was $896.2 million. The revolving facility was undrawn, with about $422 million available after letters of credit; the separate receivables financing facility was also undrawn, with $450 million capacity. The company reported compliance with debt covenants.
- Interest and debt: Net interest expense increased 13.6% in Q2 to $40.7 million and 73.3% in the first half to $82.9 million. The company made $65 million in unscheduled term-loan principal payments in the first half. Approximately $254 million of debt principal is due in December 2024.
Material changes and management commentary
- Management attributed weaker earnings primarily to lower PPE demand, including reduced COVID-related purchases, product-mix changes, inflation and higher interest expense, alongside $29.0 million of Q2 exit and realignment charges. Productivity gains and Patient Direct growth partly offset these pressures.
- Products & Healthcare Services Q2 PPE revenue declined by approximately $107 million, including a $70.5 million reduction related to glove pricing; growth in other categories offset the decline at the segment revenue level. First-half PPE revenue declined approximately $370 million.
- First-half revenue growth included $308 million of incremental Apria revenue in Q1 versus the prior-year quarter. Apria was included in 2022 results only from its March 29 acquisition date.
- DS&A expenses rose 7.8% in Q2 and 30.7% in the first half; management cited increased business support costs, benefits, wages and occupancy costs. Exit and realignment charges were $44.6 million for the first half, versus $2.9 million.
- First-half operating cash flow benefited from working-capital movements and the new receivables purchase agreement. The company received $409 million in net proceeds from receivable sales during the first half; $115 million of sold receivables remained uncollected and off the balance sheet at June 30.
Outlook, risks and unusual items
- The filing gives no numerical earnings or revenue guidance. Management said cash from operations, cash on hand and available financing are expected to meet foreseeable needs, while noting potential effects from economic conditions, borrowing costs and customer or supplier credit.
- Management expected material additional 2023 costs from its Operating Model Realignment Program and IT restructuring.
- FDA/NIOSH concerns involving certain Halyard surgical N95 respirator models led the company to stop U.S. sales of affected and similar models while investigating and retesting. The possible loss is not estimable; potential consequences include returns, recall or remediation costs, regulatory action and litigation.
- The Philips Respironics device recall may continue to create service costs, supply constraints and adverse effects on Patient Direct revenue and results; recovery of costs from the manufacturer is uncertain.
- The IRS disputes the company’s transfer-pricing treatment for tax years 2015–2018. The company believes reserves are adequate and disputes the IRS position, but an adverse outcome could materially affect financial results or cash flows.
- Other noted exposures include inflation, commodity and freight costs, foreign exchange, interest rates, product safety, reimbursement and substantial indebtedness. A 100-basis-point rate increase was estimated to reduce annual pretax earnings by about $8 million, based on June 30 borrowings and annualized receivable-sale activity.
Important facts for investors to verify
- Confirm the issuer: the provided filing identifies Owens & Minor, Inc., not Accendra Health Inc.
- Review the drivers and durability of the Products & Healthcare Services profit decline and Patient Direct growth, including Apria comparability.
- Assess the quality and sustainability of operating cash flow, particularly the effect of receivables sales and working-capital changes.
- Review debt maturities, interest-rate exposure, covenant headroom and refinancing needs ahead of the December 2024 notes maturity.
- Monitor costs and operational impact from the Halyard product investigation, Philips recall and planned restructuring; the filing does not quantify potential losses from the Halyard matter.